Passage Bio (PASG)
(Delayed Data from NSDQ)
$1.32 USD
+0.10 (8.20%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.32 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.32 USD
+0.10 (8.20%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.32 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Zacks News
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
by Zacks Equity Research
Does Passage Bio, Inc. (PASG) have what it takes to be a top stock pick for momentum investors? Let's find out.
New Strong Sell Stocks for August 12th
by Zacks Equity Research
WKHS, SPCE, PASG, LYRA, and GO have been added to the Zacks Rank #5 (Strong Sell) List on August 12, 2021
Moving Average Crossover Alert: Passage Bio (PASG)
by Zacks Equity Research
Passage Bio (PASG) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Passage Bio (PASG) Looks Good: Stock Adds 5.4% in Session
by Zacks Equity Research
Passage Bio (PASG) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio
by Zacks Equity Research
Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio
New Analyst Coverage Puts Spotlight on These 2 Stocks
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.